The treatment being tested is inhaled aprotinin, a substance that helps control inflammation by blocking certain proteins in the body. During the study, some patients will receive aprotinin through an inhaler, while others will receive a saline solution. The medication or saline solution will be given to patients who are already using breathing machines in the hospital’s intensive care unit.

The study will monitor how long patients need to use breathing machines, track their overall health status, and observe their recovery over several months. Doctors will regularly check patients’ blood samples, vital signs, and general health condition to ensure their safety throughout the treatment period. The total treatment time with the study medication can last up to six months.

The purpose of the study is to evaluate how well metoprolol tartrate works in helping patients with ARDS. Participants in the study will receive either the medication or a placebo. The study will monitor participants over a period of 28 days to see how many days they are alive and free from the need for a machine to help them breathe, known as invasive mechanical ventilation. The study will also look at other outcomes, such as the number of days spent in the intensive care unit and overall quality of life after three months.

Throughout the study, researchers will collect information on various health indicators, including the level of oxygen in the blood. This will help determine if metoprolol tartrate can improve the condition of patients with ARDS. The trial is designed to provide valuable insights into the potential use of this medication for treating ARDS and improving patient outcomes.

The purpose of the study is to determine which medication, Fentanyl or Esketamine, is safer and more effective when used as premedication. Participants in the study will receive either one of these medications or a placebo before undergoing the surfactant administration procedure. The study will monitor for any side effects and measure how well the medications work in reducing these effects.

The trial will take place over a period of time, with participants being closely observed to ensure their safety and to gather data on the effectiveness of the medications. The goal is to find out which medication leads to fewer adverse events, making it the preferred choice for premedication in this procedure.

The main goal of the study is to see if Pirfenidone can increase the number of days patients can breathe without the help of a ventilator by day 28. Participants in the study will receive either Pirfenidone or a placebo, and their progress will be monitored over a period of 28 days. The study will also look at other outcomes, such as the number of days patients spend outside of the intensive care unit (ICU), improvements in lung function, and overall quality of life.

Throughout the study, various tests and assessments will be conducted to gather information on the effectiveness and safety of Pirfenidone. These include checking for changes in lung tissue using high-resolution computed tomography (CT) scans, measuring heart function with echocardiography, and evaluating physical performance through a six-minute walk test. The study aims to provide valuable insights into the potential benefits of Pirfenidone for patients with ARDS.

The purpose of the study is to see how these medications affect the occurrence of blood clots during ECMO therapy. Participants will be randomly assigned to receive one of the three medications. The study will monitor the incidence of blood clots, such as pulmonary embolism and deep vein thrombosis, as well as any bleeding events. The study will last for a period of up to six months for each participant.

Throughout the study, participants will receive regular check-ups to monitor their health and the effectiveness of the medication they are receiving. The goal is to determine which medication is most effective in preventing blood clots without causing significant bleeding. This information will help improve treatment strategies for patients requiring ECMO support in the future.

The main goal of the study is to determine if FX06 can reduce the time it takes for patients to start breathing without assistance. Participants in the study will receive either FX06 or a placebo, and their progress will be monitored over a period of 28 days. The study will look at various factors, including how the disease progresses or improves, lung function, and overall survival. Other aspects such as inflammation levels, hospital stay duration, and safety will also be assessed.

Throughout the study, participants will undergo regular check-ups to monitor their health and the effects of the treatment. The study aims to provide valuable insights into whether FX06 can be an effective treatment for ARDS, potentially leading to better outcomes for patients with this challenging condition.

The purpose of the study is to evaluate how effective and safe Reparixin is when used alongside the standard care for ARDS. Participants in the study will receive either Reparixin or a placebo, and their progress will be monitored over a period of time. The study aims to see if Reparixin can help patients recover more quickly and reduce their need for mechanical ventilation, which is a machine that helps with breathing.

Throughout the study, researchers will observe changes in the patients’ lung function and overall health. They will also look at specific markers in the blood that are linked to inflammation. The study will last for several weeks, and the results will help determine if Reparixin can be a beneficial treatment for people with ARDS.

The trial will involve two groups of patients: those who receive dexmedetomidine and those who do not. The medication will be given through an injection into a vein. Researchers will use a special imaging technique called PET-MRI to look at the brain and measure inflammation levels. This will be done 24 months after the patients have been discharged from intensive care. The study aims to see if dexmedetomidine can help protect the brain and improve cognitive function, which includes memory and thinking skills.

Another part of the study will look at how dexmedetomidine affects brain health by using brain scans and clinical assessments. Researchers will also explore biological factors that might influence brain inflammation after severe COVID-19 infection. The goal is to better understand how to manage brain health in patients recovering from COVID-19-related ARDS and to identify any risk factors that might contribute to long-term brain inflammation.

The treatment being tested involves giving patients either high doses of Laroscorbine (vitamin C solution) or sodium chloride solution (placebo) through their veins for 4 days. The vitamin C dose used in this study is higher than what is normally given to patients. Both solutions will be given as an injection or infusion directly into the bloodstream.

The purpose of this research is to determine if high-dose vitamin C can reduce the chances of death or ongoing organ problems in patients with severe sepsis and ARDS. Organ problems include the continued need for breathing machines, medications to maintain blood pressure, or special filtering of the blood when kidneys are not working properly. Patients will be monitored for 28 days to see how the treatment affects their recovery.

The purpose of the study is to evaluate how many days patients can breathe without the help of a ventilator. Participants in the study will receive Kineret, which is the brand name for anakinra, administered as a solution for injection. The study will compare the effects of this treatment on patients with ARDS to see if it can help improve their breathing and reduce the need for mechanical ventilation.

Throughout the study, researchers will monitor various health outcomes, including survival rates and improvements in lung function. The study will also assess the overall health of participants by looking at factors like organ function and pressure in the lungs. The goal is to gather information that could lead to better treatment options for people suffering from ARDS.

The purpose of the study is to evaluate how well rhu-pGSN works in combination with the standard care that patients with ARDS usually receive. Participants in the study will be randomly assigned to receive either rhu-pGSN or a placebo, along with their regular treatment. The study will monitor participants over a period of time to assess their recovery and any side effects they may experience. The main focus will be on the survival rate of participants and their need for respiratory support, such as ventilators, during the study period.

Throughout the study, researchers will collect information on how many days participants can breathe without the help of a ventilator and how long they stay in the hospital. The study will also look at the overall safety of rhu-pGSN by tracking any new or worsening health issues that occur. This research aims to provide valuable insights into whether rhu-pGSN can improve outcomes for patients suffering from ARDS due to infections like pneumonia.

In this study, patients who have experienced severe trauma and are in the intensive care unit (ICU) will receive dornase alfa through inhalation. This means the medication is given as a mist that is breathed into the lungs. The study will compare the effects of dornase alfa with a placebo to see if it helps in reducing the incidence of moderate to severe ARDS during the first week after the trauma. A placebo is a substance with no active medication, used to compare the effects of the actual drug.

The trial will take place over a period of time, with patients being monitored closely to observe any changes in their condition. The goal is to determine if early treatment with dornase alfa can effectively lower the risk of developing ARDS in patients who have suffered from severe trauma and are receiving mechanical ventilation in the ICU. This research could provide valuable insights into improving care for trauma patients and potentially preventing serious lung complications.

The purpose of the study is to determine if inhaled sevoflurane can improve oxygen levels in the blood better than traditional medications. The other medications that may be used in the study include dexmedetomidine, cisatracurium, midazolam, and propofol, which are all given through a vein. These medications are commonly used to help keep patients comfortable while they are receiving support from a breathing machine.

During the study, patients will receive either sevoflurane through a breathing system or the standard medications through their veins for up to 5 days. The doctors will monitor how well patients’ lungs work by measuring oxygen levels and checking for signs of lung problems. They will also track other important health information such as infections, time spent on breathing machines, and length of stay in the intensive care unit.

The treatment being studied involves a solution for injection called [68Ga]FAPI-46. This is a chemical substance that helps to highlight the activity of fibrogenic cells in the lungs when viewed through the PET/CT scan. The purpose of the study is to understand how the activity of these cells relates to the patient’s recovery, including their survival after 28 days, the number of days they can breathe without a ventilator, and the length of their stay in the intensive care unit (ICU).

During the study, patients with non-resolving ARDS who are on mechanical ventilation will receive the [68Ga]FAPI-46 injection. The PET/CT scan will then be used to visualize the activity of the fibrogenic cells in their lungs. The study aims to gather information on how this activity is connected to various health outcomes, such as the patient’s respiratory condition and certain markers in their blood that indicate inflammation. The study will also evaluate the PET/CT procedure itself to ensure it is safe and effective for patients.

The purpose of the study is to evaluate how effective Idefirix is when used alongside the standard care for patients with severe ANCA-associated vasculitis and lung bleeding. Participants in the study will receive either Idefirix or a placebo, in addition to the usual treatments for their condition. The study will monitor how quickly the levels of ANCA antibodies in the blood decrease after treatment, as well as other health outcomes such as lung and kidney function, and overall safety.

Throughout the study, researchers will observe participants for any changes in their condition, including improvements in lung function and any potential side effects. The study aims to provide valuable information on the potential benefits and safety of using Idefirix in treating this serious form of vasculitis. The trial is expected to continue until mid-2026, with recruitment of participants starting in 2024.